Non-Small Cell Lung Cancer Pipeline, FDA Approvals, Clinical Trials Developments and Companies (Updated)

DelveInsight's, "Non-Small-Cell Lung Cancer Pipeline Insight 2023" report provides comprehensive insights about 135+ Non-Small Cell Lung Cancer Companies and 150+ pipeline drugs in the Non-Small-Cell Lung cancer (NSCLC) pipeline landscape. It covers the Non-Small Cell Lung Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Non-Small Cell Lung Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Non-Small Cell Lung Cancer Pipeline Report
• DelveInsight's Non-Small Cell Lung Cancer pipeline report depicts a robust space with 135+ active players working to develop 150+ pipeline therapies for Non-Small Cell Lung Cancer treatment.
• The leading Non-Small Cell Lung Cancer Companies working in the market include BridgeBio Pharma, Daiichi Sankyo, EMD Serono/Merck, BridgeBio Pharma, Abbvie/Pfizer, Eli Lilly and Company, BioNTech SE, Shenzhen TargetRx, Taiho Pharmaceutical, Chong Kun Dang, Bristol Myers Squibb, Innovent Biologics, Xuanzhu Biopharmaceutical, Bayer, GeneScience Pharmaceuticals, InventisBio, Apollomics, Imugene, Ono Pharmaceutical/Pierre Fabre, Jiangsu Hengrui Medicine Co., Bristol-Myers Squibb, Surface Oncology, Inhibrx, Sinocelltech, Mirati Therapeutics, REVOLUTION Medicines, Yong Shun Technology Development, Iovance Biotherapeutics, Galecto Biotech, and others.
• Promising Non-Small Cell Lung Cancer Pipeline Therapies in the various stages of development include Trastuzumab deruxtecan, DS-1062a, Docetaxel, Pembrolizumab (MK-3475) 200 mg, Domvanalimab, Zimberelimab, Quemliclustat, BNT116, Cemiplimab, SKB264, Carboplatin, Osimertinib, and others.
• December 2023: Merck Sharp & Dohme LLC announced a study of Phase 3 clinical trials for V940 and Pembrolizumab. The goal of this study is to evaluate V940 plus pembrolizumab versus placebo plus pembrolizumab for the adjuvant treatment of completely resected (R0) Stage II, IIIA, IIIB (with nodal involvement [N2]) non-small cell lung cancer (NSCLC). The primary hypothesis is that V940 plus pembrolizumab is superior to placebo plus pembrolizumab with respect to disease-free survival (DFS) as assessed by the investigator.
• December 2023: AstraZeneca announced a study of Phase 2 clinical trials for Durvalumab, Oleclumab, Monalizumab, MEDI5752, and AZD0171. The study is intended to assess the safety and efficacy of perioperative treatment with Durvalumab in combination with Oleclumab, Monalizumab or AZD0171 and platinum doublet chemotherapy; or MEDI5752 in combination with platinum doublet chemotherapy or datopotamab deruxtecan (Dato-DXd) in combination with durvalumab and single agent platinum chemotherapy in participants with resectable, early-stage non-small cell lung cancer.
• December 2023: Gilead Sciences announced a study of Phase 3 clinical trials for Zimberelimab, Domvanalimab, Pembrolizumab, Carboplatin, and Cisplatin. The primary objective of this study is to compare the effect of zimberelimab (ZIM) and domvanalimab (DOM) in combination with chemotherapy relative to pembrolizumab (PEMBRO) in combination with chemotherapy on progression-free survival (PFS) and overall survival (OS) in patients with untreated metastatic non-small cell lung cancer with no actionable genomic alteration.

Request a sample and discover the recent advances in Non-Small Cell Lung Cancer Treatment Drugs @ Non-Small Cell Lung Cancer Pipeline Outlook Report- https://www.delveinsight.com/report-store/non-small-cell-lung-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

The Non-Small Cell Lung Cancer pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Non-Small Cell Lung Cancer drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Non-Small Cell Lung Cancer clinical trial landscape.

Non-Small Cell Lung Cancer Overview
Non-small-cell lung cancer (NSCLC) is any type of epithelial lung cancer other than small-cell lung cancer (SCLC) and accounts for about 85% of all lung cancers. There are three kinds of NSCLC tumors: a) Adenocancer starts in cells inside air sacs that make mucus and other substances, often in the outer parts of your lungs. It's the most common kind of lung cancer among both smokers and nonsmokers and people under 45. It often grows more slowly than other lung cancers. b) Squamous cell lung cancer starts in cells that line the inner airways of the lungs.

Find out more about Non-Small Cell Lung Cancer Treatment Landscape @ Drugs for Non-Small Cell Lung Cancer Treatment- https://www.delveinsight.com/sample-request/non-small-cell-lung-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Non-Small Cell Lung Cancer Emerging Drugs Profile
• Datopotamab deruxtecan: Daiichi Sankyo
• JDQ443: Novartis
• MRTX849: Mirati Therapeutics
• INBRX-106: Inhibrx

Non-Small Cell Lung Cancer Pipeline Therapeutics Assessment
There are approx. 135+ key Non-Small Cell Lung Cancer companies which are developing the Non-Small Cell Lung Cancer therapies. The Non-Small Cell Lung Cancer companies which have their Non-Small-Cell Lung cancer (NSCLC) drug candidates in the most advanced stage, i.e. Phase III include Daiichi Sankyo.

DelveInsight's Non-Small Cell Lung Cancer Pipeline report covers around 150+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Non-Small-Cell Lung cancer Pipeline Report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Intranasal
• Intrathecal
• Intravenous
• Oral
• Oral/Intravenous
• Parenteral
• Subcutaneous
• Subcutaneous/Intramuscular
• Transdermal

Non-Small Cell Lung Cancer Products have been categorized under various Molecule types such as
• Antisense oligonucleotide
• Gene therapy
• Hormones
• Neuropeptides
• Oligonucleotides
• Small Molecule
• Triglyceride

Learn more about the emerging Non-Small Cell Lung Cancer Pipeline Therapies @ Non-Small Cell Lung Cancer Clinical Trials Assessment- https://www.delveinsight.com/sample-request/non-small-cell-lung-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Non-Small Cell Lung Cancer Pipeline Report
• Coverage- Global
• Non-Small Cell Lung Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Non-Small Cell Lung Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Non-Small Cell Lung Cancer Companies- BridgeBio Pharma, Daiichi Sankyo, EMD Serono/Merck, BridgeBio Pharma, Abbvie/Pfizer, Eli Lilly and Company, BioNTech SE, Shenzhen TargetRx, Taiho Pharmaceutical, Chong Kun Dang, Bristol Myers Squibb, Innovent Biologics, Xuanzhu Biopharmaceutical, Bayer, GeneScience Pharmaceuticals, InventisBio, Apollomics, Imugene, Ono Pharmaceutical/Pierre Fabre, Jiangsu Hengrui Medicine Co., Bristol-Myers Squibb, Surface Oncology, Inhibrx, Sinocelltech, Mirati Therapeutics, REVOLUTION Medicines, Yong Shun Technology Development, Iovance Biotherapeutics, Galecto Biotech, and others.
• Non-Small Cell Lung Cancer Pipeline Therapies in the various stages of development include Trastuzumab deruxtecan, DS-1062a, Docetaxel, Pembrolizumab (MK-3475) 200 mg, Domvanalimab, Zimberelimab, Quemliclustat, BNT116, Cemiplimab, SKB264, Carboplatin, Osimertinib, and others.

Dive deep into rich insights for new drugs for Non-Small Cell Lung Cancer treatment, Visit @ Non-Small Cell Lung Cancer Market Drivers and Barriers, and Future Perspective- https://www.delveinsight.com/sample-request/non-small-cell-lung-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Non-Small Cell Lung Cancer Executive Summary
3. Non-Small-Cell Lung cancer Overview
4. Non-Small Cell Lung Cancer Pipeline Therapeutics
5. Non-Small Cell Lung Cancer Therapeutic Assessment
6. Non-Small-Cell Lung cancer DelveInsight's Analytical Perspective
7. Mid Stage Products (Phase III)
8. Datopotamab deruxtecan: Daiichi Sankyo
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. RMC-4630: REVOLUTION Medicines
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. GB 1211: BridgeBio Pharma
15. Drug profiles in the detailed report…..
16. Early Stage Products (Phase I)
17. BBP 398: BridgeBio Pharma.
18. Drug profiles in the detailed report…..
19. Preclinical Stage Products
20. Drug name: Company name
21. Drug profiles in the detailed report…..
22. Inactive Products
23. Non-Small-Cell Lung Cancer Companies
24. Non-Small-Cell Lung Cancer Key Products
25. Non-Small-Cell Lung Cancer Unmet Needs
26. Non-Small-Cell Lung Cancer Market Drivers and Barriers
27. Non-Small-Cell Lung Cancer Future Perspectives and Conclusion
28. Non-Small-Cell Lung Cancer Analyst Views
29. Non-Small-Cell Lung Cancer Companies
30. Appendix

For further information on the Non-Small Cell Lung Cancer Pipeline therapeutics, reach out to Non-Small Cell Lung Cancer Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/non-small-cell-lung-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

List of Important Published Links

https://connectgalaxy.com/post/146081_syphilis-a-sexually-transmitted-bacterial-infection-caused-by-treponema-pallidum.html
https://www.thebostoncalendar.com/user/74833
https://wrongplanet.net/author/dennydones9999/
https://bookmark.hiauthors.com/story/syphilis-market
https://www.openhumans.org/member/anniethomas/
https://cynochat.com/read-blog/160375
https://hitrecord.org/users/dennydones9999/records
https://biiut.com/read-blog/918
https://nimmansocial.com/story5840956/syphilis-market
https://bookmarkbirth.com/story15878475/syphilis-market
https://biomolecula.ru/authors/25303
https://discuss.machform.com/u/dennydones9191
https://dagshub.com/dennydones9191
https://careerkarma.com/profile/clr7d7z0c04v2lf3k5lrx9vyr/
https://gotech.mn.co/posts/48477911
https://landmarknew.mn.co/posts/48477947
https://infiniteabundance.mn.co/posts/48478016
https://wellbeingmatters.mn.co/posts/48478424
https://vrjam.mn.co/posts/48478544
https://decidim.santcugat.cat/profiles/dennydones9/activity
https://haveagood.holiday/users/336105
https://participa.rubi.cat/profiles/dennydones9191/activity
https://forum.callofwar.com/index.php?user/60304-dennydones9191/#about
https://kktix.com/user/5068280
https://network-373.mn.co/posts/48353213
https://body-imagine.mn.co/posts/48353364
https://pimpmyairgun.mn.co/posts/48353478
https://gtribe.mn.co/posts/advancements-and-opportunities-in-the-vulvar-cancer-market
https://communenour.mn.co/posts/emerging-trends-and-market-dynamics-in-vulvar-cancer-treatment
https://synkretic.mn.co/posts/understanding-the-vulvar-cancer-market-trends-challenges-and-innovations
https://jlfa2020.mn.co/members/16644457
https://dbook.mn.co/posts/48401881
https://lxgonline.mn.co/posts/navigating-the-landscape-of-hypertriglyceridemia-market-current-trends-and-future-prospects
https://www.penname.me/@dennydones99
https://community.fyers.in/member/7Yldtdsvui
https://spurstartup.mn.co/posts/48406045
https://pressurecooker.mn.co/posts/48406225
https://regenerative-future.mn.co/posts/navigating-the-hypertriglyceridemia-market-innovations-and-challenges
https://commiss.io/dennydones
https://www.pledgeme.co.nz/profiles/221820/
https://brave-comfort.mn.co/posts/48409148
https://gamebook.mn.co/posts/navigating-the-landscape-of-the-hypertriglyceridemia-market

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/stem-cell-market

This release was published on openPR.